{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:42:10Z","timestamp":1787042530486,"version":"build-2736575974"},"reference-count":110,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Project POR Puglia FESR-FSE 2014-2020 Azione 1.6.  Innonetwork  progetto D.I.V.A.","award":["cod. JD6EDJ7"],"award-info":[{"award-number":["cod. JD6EDJ7"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The therapeutic approach to Chronic Myeloid Leukemia (CML) has changed since the advent of the tyrosine kinase inhibitor (TKI) imatinib, which was then followed by the second generation TKIs dasatinib, nilotinib, and, finally, by ponatinib, a third-generation drug. At present, these therapeutic options represent the first-line treatment for adults. Based on clinical experience, imatinb, dasatinib, and nilotinib have been approved for children even though the studies that were concerned with efficacy and safety toward pediatric patients are still awaiting more specific and high-quality data. In this scenario, it is of utmost importance to prospectively validate data extrapolated from adult studies to set a standard therapeutic management for pediatric CML by employing appropriate formulations on the basis of pediatric clinical trials, which allow a careful monitoring of TKI-induced adverse effects especially in growing children exposed to long-term therapy.<\/jats:p>","DOI":"10.3390\/ijms21124469","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T07:14:19Z","timestamp":1592982859000},"page":"4469","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML"],"prefix":"10.3390","volume":"21","author":[{"given":"Francesca","family":"Carofiglio","sequence":"first","affiliation":[{"name":"Dipartimento di Farmacia Scienze del Farmaco Universit\u00e0 degli Studi di Bari \u201cAldo Moro\u201d, via Orabona 4, Bari 70125, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lopalco","sequence":"additional","affiliation":[{"name":"Dipartimento di Farmacia Scienze del Farmaco Universit\u00e0 degli Studi di Bari \u201cAldo Moro\u201d, via Orabona 4, Bari 70125, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lopedota","sequence":"additional","affiliation":[{"name":"Dipartimento di Farmacia Scienze del Farmaco Universit\u00e0 degli Studi di Bari \u201cAldo Moro\u201d, via Orabona 4, Bari 70125, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Cutrignelli","sequence":"additional","affiliation":[{"name":"Dipartimento di Farmacia Scienze del Farmaco Universit\u00e0 degli Studi di Bari \u201cAldo Moro\u201d, via Orabona 4, Bari 70125, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6533-5539","authenticated-orcid":false,"given":"Orazio","family":"Nicolotti","sequence":"additional","affiliation":[{"name":"Dipartimento di Farmacia Scienze del Farmaco Universit\u00e0 degli Studi di Bari \u201cAldo Moro\u201d, via Orabona 4, Bari 70125, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzio","family":"Denora","sequence":"additional","affiliation":[{"name":"Dipartimento di Farmacia Scienze del Farmaco Universit\u00e0 degli Studi di Bari \u201cAldo Moro\u201d, via Orabona 4, Bari 70125, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9430-7972","authenticated-orcid":false,"given":"Angela","family":"Stefanachi","sequence":"additional","affiliation":[{"name":"Dipartimento di Farmacia Scienze del Farmaco Universit\u00e0 degli Studi di Bari \u201cAldo Moro\u201d, via Orabona 4, Bari 70125, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Leonetti","sequence":"additional","affiliation":[{"name":"Dipartimento di Farmacia Scienze del Farmaco Universit\u00e0 degli Studi di Bari \u201cAldo Moro\u201d, via Orabona 4, Bari 70125, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","article-title":"Mechanisms of cardiomyopathy associated with tyrosine kinase inhibitor cancer therapeutics","volume":"118","author":"Chen","year":"2008","journal-title":"Circulation"},{"key":"ref_2","unstructured":"(2020, January 20). Tyrosine-kinase-inhibitor, Available online: https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/targeted-therapies\/targeted-therapies-fact-sheet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/1097-0142(19950115)75:2<464::AID-CNCR2820750209>3.0.CO;2-E","article-title":"Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results","volume":"75","author":"Cortes","year":"1995","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/1947601912462126","article-title":"The Ins and Outs of Bcr-Abl Inhibition","volume":"3","author":"Reddy","year":"2012","journal-title":"Genes Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jmb.2018.01.013","article-title":"EzMol: A web server wizard for the rapid visualisation and image production of protein and nucleic acid structures","volume":"430","author":"Reynolds","year":"2018","journal-title":"J. Mol. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1586\/ehm.10.21","article-title":"Allogeneic hematopoietic cell transplantation: The state of the art","volume":"3","author":"Gyurkocza","year":"2010","journal-title":"Expert Rev. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00062752-200401000-00006","article-title":"Mechanisms and implications of imatinib resistance mutations in BCR-ABL","volume":"11","author":"Nardi","year":"2004","journal-title":"Curr. Opin. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1182\/blood-2003-03-0993","article-title":"Functional consequence of MDR1 expression on imatinib intracellular concentrations","volume":"102","author":"Widmer","year":"2003","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/leu.2015.170","article-title":"OCT1 and imatinib transport in CML: Is it clinically relevant?","volume":"29","author":"Watkins","year":"2015","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.drudis.2019.11.005","article-title":"Human ether-\u00e0-go-go-related potassium channel: Exploring SAR to improve drug design","volume":"25","author":"Cavalluzzi","year":"2020","journal-title":"Drug Discov. Today"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.clml.2016.02.028","article-title":"Imatinib Intolerance Is Associated with Blastic Phase Development in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia","volume":"16","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in Imatinib-Resistant Philadelphia Chromosome\u2013Positive Leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res."},{"key":"ref_14","first-page":"18","article-title":"Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase","volume":"2","author":"Bose","year":"2013","journal-title":"Leuk. Res. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib Resistant BCR\/ABL Mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance","volume":"16","author":"Shakespeare","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9244","DOI":"10.1073\/pnas.0600001103","article-title":"Activity of dual SRC-ABL inhibitors highlights the role of BCR\/ABL kinase dynamics in drug resistance","volume":"103","author":"Azam","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/sj.leu.2402194","article-title":"Clinicopathologic characteristics of leukemia in Japanese children and young adults","volume":"15","author":"Horibe","year":"2001","journal-title":"Leukemia"},{"key":"ref_20","unstructured":"Bleyer, A., O\u2019Leary, M., Barr, R., and Ries, L.A.G. (2006). Leukemias. Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975\u20132000, National Cancer Institute, NIH."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1542\/peds.2004-2473","article-title":"Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia","volume":"116","author":"Millot","year":"2005","journal-title":"Pediatrics"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","article-title":"Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: Results of the French national phase IV trial","volume":"29","author":"Millot","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3109\/10428194.2012.745525","article-title":"Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009","volume":"54","author":"Chen","year":"2013","journal-title":"Leuk. Lymph."},{"key":"ref_24","unstructured":"(2020, January 20). Cancer Research UK. Available online: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/leukaemia-cml\/incidence#heading-One."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40265-014-0207-7","article-title":"First-Line Treatment of Newly Diagnosed Elderly Patients with Chronic Myeloid Leukemia: Current and Emerging Strategies","volume":"74","author":"Gugliotta","year":"2014","journal-title":"Drugs"},{"key":"ref_26","unstructured":"Ries, L.A.G., Smith, M.A., Gurney, J.G., Linet, M., Tamra, T., Young, J.L., and Bunin, G.R. (2020, June 22). Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975\u20131995, Available online: https:\/\/seer.cancer.gov\/archive\/publications\/childhood\/."},{"key":"ref_27","unstructured":"North American Association of Central Cancer Registries (2020, February 17). NAACCR Fast Stats: An Interactive Tool for Quick Access to Key NAACCR Cancer Statistics. Available online: http:\/\/www.naaccr.org\/."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood-2015-06-648667","article-title":"Pediatric chronic myeloid leukemia is a unique disease that requires a different approach","volume":"127","author":"Hijiya","year":"2016","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/s41375-018-0157-2","article-title":"Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia","volume":"32","author":"Ernst","year":"2018","journal-title":"Leukemia"},{"key":"ref_30","first-page":"1108","article-title":"Chronic Myeloid Leukemia, Version 1.2019 NCCN clinical practice guidelines in oncology","volume":"16","author":"Radich","year":"2018","journal-title":"JNCCN"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3324\/haematol.2017.170035","article-title":"Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents","volume":"102","author":"Millot","year":"2017","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00277-015-2367-2","article-title":"Can prognostic scoring system for chronic myeloid leukemia as established in adults be applied to pediatric patients?","volume":"94","author":"Salas","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2011.03.046","article-title":"Distinct Impact of Imatinib on Growth at Prepubertal and Pubertal Ages of Children with Chronic Myeloid Leukemia","volume":"159","author":"Shima","year":"2011","journal-title":"J. Pediatr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1097\/MPH.0000000000001624","article-title":"Discontinuation of Imatinib in a Child with Chronic Myeloid Leukemia","volume":"42","author":"Jeyaraman","year":"2020","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): A prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pcl.2014.09.008","article-title":"Chronic myeloid leukemia in children: Clinical findings, management, and unanswered questions","volume":"62","author":"Hijiya","year":"2015","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/s41375-018-0179-9","article-title":"Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: Results from a phase III trial","volume":"32","author":"Suttorp","year":"2018","journal-title":"Leukemia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/bjh.13103","article-title":"Treatment-free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia","volume":"168","author":"Giona","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/minf.201501017","article-title":"Mind the gap! A journey towards computational toxicology","volume":"35","author":"Mangiatordi","year":"2016","journal-title":"Mol. Inform."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/annonc\/mdu490","article-title":"A GIMEMA CML Working Party. Differences among young adults, adults and elderly chronic myeloid leukemia patients","volume":"26","author":"Castagnetti","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/bmt.2014.55","article-title":"Hematopoietic SCT in Europe: Data and trends in 2012 with special consideration of pediatric trans-plantation","volume":"49","author":"Passweg","year":"2014","journal-title":"Bone Marrow Trans."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bbmt.2016.02.015","article-title":"Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis","volume":"22","author":"Chaudhury","year":"2016","journal-title":"Biol. Blood Marrow Trans."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1182\/blood.V120.21.3741.3741","article-title":"The International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I- CML-Ped-Study): Objectives and preliminary results","volume":"120","author":"Millot","year":"2012","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1176\/appi.psy.46.1.34","article-title":"Psychosocial function after hematopoietic stem cell transplantation","volume":"46","author":"Chang","year":"2005","journal-title":"Psychosomatics"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/bmt.2013.232","article-title":"Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus Imatinib","volume":"49","author":"Mo","year":"2014","journal-title":"Bone Marrow Trans."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e2782","DOI":"10.1002\/pbc.27827","article-title":"Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children\u2019s Oncology Group CML Working Group","volume":"66","author":"Athale","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Intergroupe Fran\u00e7ais des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_52","unstructured":"National Comprehensive Cancer Network (2020, June 22). NCCN Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia, Version 1.2020. Available online: https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/cml-patient.pdf."},{"key":"ref_53","first-page":"313","article-title":"Duration of deep molecular response has most impact on the success of cessation of tyrosine kinase inhibitor treatment in chronic myeloid leukemia\u2014results from the EURO-SKI trial","volume":"130","author":"Saussele","year":"2017","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","article-title":"Pregnancy among patients with chronic myeloid leukemia treated with imatinib","volume":"24","author":"Ault","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ajh.24186","article-title":"The impact of dasatinib on pregnancy outcomes","volume":"90","author":"Cortes","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","article-title":"Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: A tyrosine kinase inhibitor withdrawal syndrome?","volume":"32","author":"Richter","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"France Intergroupe des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: Interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/pbc.24521","article-title":"Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase","volume":"61","author":"Millot","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_62","unstructured":"(2020, January 20). FDA Approves Gleevec for Children with Acute Lymphoblastic Leukemia, Available online: https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm336868.html."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0029-1239529","article-title":"Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: Results from the prospective trial CML-paed I","volume":"221","author":"Suttorp","year":"2009","journal-title":"Klin. Padiatr."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/asheducation-2010.1.368","article-title":"Treatment of pediatric chronic myeloid leukemia in the year 2010: Use of tyrosine kinase inhibitors and stem-cell transplantation","volume":"2010","author":"Suttorp","year":"2010","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood-2003-09-3032","article-title":"Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: Results from a Children\u2019s Oncology Group phase 1 study","volume":"104","author":"Champagne","year":"2004","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3345\/kjp.2011.54.3.111","article-title":"The treatment of pediatric chronic myelogenous leukemia in the imatinib era","volume":"54","author":"Lee","year":"2011","journal-title":"Korean J. Pediatr."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s12185-010-0764-9","article-title":"Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era","volume":"93","author":"Muramatsu","year":"2011","journal-title":"Int. J. Hematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/sj.leu.2404051","article-title":"Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation","volume":"20","author":"Millot","year":"2006","journal-title":"Leukemia"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/leu.2016.20","article-title":"Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: Long-term observation in CML Study IV","volume":"30","author":"Miranda","year":"2016","journal-title":"Leukemia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: Data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia","volume":"355","author":"Drucker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukaemia: Incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"Apperley","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_73","first-page":"CR721","article-title":"Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment","volume":"18","author":"Jaeger","year":"2010","journal-title":"Med. Sci. Monit."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.3324\/haematol.2012.067447","article-title":"Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty","volume":"98","author":"Giona","year":"2013","journal-title":"Haematologica"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1016\/j.ejca.2014.10.007","article-title":"Growth deceleration in children treated with imatinib for chronic myeloid leukaemia","volume":"50","author":"Millot","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/17512433.2018.1398644","article-title":"Pharmacology and pharmacokinetics of imatinib in pediatric patients","volume":"11","author":"Suttorp","year":"2018","journal-title":"Exp. Rev. Clin. Pharm."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/bjh.13453","article-title":"Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: The Italian experience","volume":"170","author":"Giona","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_78","unstructured":"(2020, January 20). FDA Approved Dasatinib for Pediatric Patients, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-dasatinib-pediatric-patients-cml."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1200\/JCO.2017.75.9597","article-title":"Dasatinib in Pediatric Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial","volume":"36","author":"Gore","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_80","unstructured":"(2020, January 20). FDA-approves-nilotinib-pediatric-patients, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nilotinib-pediatric-patients-newly-diagnosed-or-resistantintolerant-ph-cml-chronic."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood.2019000069","article-title":"Phase 2 study of nilotinib in pediatric patients with philadelphia chromosome-positive chronic myeloid leukemia","volume":"134","author":"Hijiya","year":"2019","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"ref_84","unstructured":"(2020, January 20). EU Nilotib Approval for Children. Available online: https:\/\/www.novartis.com\/news\/media-releases\/novartis-drug-tasignar-nilotinib-secures-eu-approval-first-and-second-line-treatment-ph-cml-cp-children."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/pbc.25551","article-title":"Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib","volume":"62","author":"Nickel","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.critrevonc.2017.10.002","article-title":"Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel","volume":"120","author":"Cervantes","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.HS9.0000559880.43992.63","article-title":"Ponatinib In Childhood Philadelphia Positive Leukemias: The Experience of The International Registry of Childhood Chronic Myleloid Leukemia I-Cml-Ped-Study","volume":"3","author":"Millot","year":"2019","journal-title":"Hemasphere"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1592\/phco.31.2.164","article-title":"Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs","volume":"31","author":"Lam","year":"2011","journal-title":"Pharmacotherapy"},{"key":"ref_90","unstructured":"(2009, August 18). Glivec Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/glivec-epar-product-information_it.pdf."},{"key":"ref_91","unstructured":"(2009, August 18). Sprycel Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sprycel-epar-product-information_it.pdf."},{"key":"ref_92","unstructured":"(2009, July 11). Iclusig Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/iclusig-article-20-procedure-product-information_it.pdf."},{"key":"ref_93","unstructured":"(2009, July 11). Tasigna Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tasigna-epar-product-information_it.pdf."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1182\/blood-2011-10-380774","article-title":"How I treat childhood CML","volume":"23","author":"Andolina","year":"2012","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/bjh.12977","article-title":"Managing children with chronic myeloid leukaemia (CML): Recommendations for the management of CML in children and young people up to the age of 18 years","volume":"167","author":"Baruchel","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1007\/s00277-015-2323-1","article-title":"Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients","volume":"94","author":"Hochhaus","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Cutrignelli, A., Sanarica, F., Lopalco, A., Lopedota, A., Laquintana, V., Franco, M., Boccanegra, B., Mantuano, P., De Luca, A., and Denora, N. (2019). Dasatinib\/HP-\u03b2-CD Inclusion Complex Based Aqueous Formulation as a Promising Tool for the Treatment of Paediatric Neuromuscular Disorders. Int. J. Mol. Sci., 30.","DOI":"10.3390\/ijms20030591"},{"key":"ref_98","unstructured":"Melville, N.A. (2017, January 22\u201325). Dasatinib in Children: An Effective Alternative to Imatinib. Proceedings of the European Hematology Association (EHA) 2017 Congress, Madrid, Spain."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2012.46.8280","article-title":"Dasatinib in Children and Adolescent With Relapsed or Refractory Leukemia: Results of the CA180-018 Phase I Dose-Escalation Study of the innovative Therapies for Children With Cancer Consortium","volume":"31","author":"Zwaan","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_100","unstructured":"Allen, L.V. (2005). The Art and Science of Pharmaceutical Compounding, APhA Publications. [2nd ed.]."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.clinthera.2008.11.020","article-title":"Extemporaneous drug formulations","volume":"30","author":"Nahata","year":"2008","journal-title":"Clin. Ther."},{"key":"ref_102","unstructured":"Allen, L.V. (2003). Compounding, stability and beyond-use dates. Secundum. Artem., 7, Available online: www.paddocklabs.com."},{"key":"ref_103","first-page":"25","article-title":"Extemporaneous formulations: Problems and solutions","volume":"1","author":"Woods","year":"1997","journal-title":"Paediatr. Perinatal. Drug Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bcp.12268","article-title":"Formulations for children: Problems and solutions","volume":"79","author":"Batchelor","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"118922","DOI":"10.1016\/j.ijpharm.2019.118922","article-title":"Taste masking of propranolol hydrochloride by microbeads of EUDRAGIT\u00ae E PO obtained with prilling technique for paediatric oral administration","volume":"574","author":"Lopalco","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"118820","DOI":"10.1016\/j.ijpharm.2019.118820","article-title":"Thiolated hydroxypropyl-\u03b2-cyclodextrin as mucoadhesive excipient for oral delivery of budesonide in liquid paediatric formulation","volume":"572","author":"Laquintana","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ejps.2018.11.013","article-title":"Pharmaceutical preformulation studies and paediatric oral formulations of sodium dichloroacetate","volume":"127","author":"Lopalco","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1182\/blood.2018882233","article-title":"How I treat chronic myeloid leukemia in children and adolescents","volume":"133","author":"Hijiya","year":"2019","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/pbc.23031","article-title":"Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children\u2019s Oncology Group","volume":"57","author":"Champagne","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/ped.12876","article-title":"Optimal management for pediatric chronic myeloid leukemia","volume":"58","author":"Tanizawa","year":"2016","journal-title":"Ped. Int."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/12\/4469\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:41:56Z","timestamp":1760175716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/12\/4469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":110,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["ijms21124469"],"URL":"https:\/\/doi.org\/10.3390\/ijms21124469","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,23]]}}}